Why Participants Leave: Recent Evidence on Trial Retention
Published September 2026 — Recent published studies report dropout ranging from under 8% in a Phase 1 unit to 29% in a long Alzheimer's prevention trial, with trial length, practical burden, and adverse events as the recurring reasons participants leave.
Retention Depends on the Trial and on the Burden
Every participant who leaves a trial early costs the study statistical power and costs the site the effort already invested. Dropout rates vary enormously between trials, which makes general benchmarks hard to apply.
This brief reviews several recently published studies covering different settings: a Phase 1 unit, a long prevention trial, a decentralized trial, and a synthesis of participants' own reasons for leaving. Taken together they show which factors drive dropout and which are within a site's influence.
Key Findings
A five-year retrospective analysis of a Phase 1 clinical studies unit (2021–2025) reported an average post-randomization retention rate of 92.2%, improving over the period.
Adverse events accounted for 40.6% of dropouts and participant-initiated withdrawal for 38.4%. Bioequivalence studies had the lowest retention.
In the A4 preclinical Alzheimer's disease trial, 339 of 1,169 randomized participants discontinued. The main reason given was unwillingness to continue.
The decentralized COVID-RED trial reported overall dropout of 19.6% after six months, with dropout more common among participants over 50.
What Drives Dropout
The studies differ in design and population, but the reasons participants give are consistent.
Duration
A 2026 Clinical Leader report found that 60% of surveyed coordinators named trial length as the most common reason for withdrawal. The contrast between the short Phase 1 studies and the multi-year A4 trial fits that view.
Practical Burden
A qualitative synthesis of participants' reasons for non-completion found that childcare, time off work, and travel costs influenced the decision to leave. These are costs the protocol imposes and that sites and sponsors can reduce.
Retention Changes Over Time
The same synthesis describes retention as an ongoing process that ebbs and flows across the trial timeline. A participant who is committed at consent may waver months later, which argues for continued engagement throughout.
Remote Participation Is Not a Cure
The COVID-RED experience shows that decentralized designs still lose participants, and that older participants were more likely to drop out. Technology lowers travel burden but introduces its own.
Participants Want Something Back
In a 2026 single-site survey of 506 participants, 73% wanted access to their individual research results. Returning results where the protocol allows is one of the few retention measures that participants ask for directly.
Implications for Sites and Sponsors
Retention is shaped at design and sustained at the site.
For long trials, schedule regular contact between visits and assign each participant a consistent coordinator. Attention usually fades after the first few months.
Travel reimbursement, flexible visit times, and remote options for suitable visits address the reasons participants most often give for leaving.
Where a trial relies on devices or apps, provide hands-on setup and a person to call. Older participants in particular benefit from this support.
Conclusions
Dropout is not one number. It ranges from single digits in short inpatient studies to nearly a third in long outpatient trials, and the reasons are mostly foreseeable: the trial takes too long, costs the participant too much, or causes side effects.
Several of the studies cited are single-site or single-trial analyses, and their figures should not be generalized without care. The consistent finding is that reducing participant burden and maintaining contact are the measures most within a site's control.
This brief summarizes published industry research. Figures are reported as stated in the sources below and have not been independently verified by Clinitiative.
- Participant dropout and retention in a Phase 1 Clinical Studies Unit, 2021–2025
- Baseline Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Clinical Trial
- Increasing Retention in a Large-Scale Decentralized Clinical Trial: Learnings From the COVID-RED Trial
- Retention in trials: a qualitative evidence synthesis of participant reasons for non-completion
- Clinical Leader: Can a Universal Health Screening Help Stop Clinical Trial Dropouts?
Discuss These Findings with Our Team
Talk with us about what this research means for your protocol, site selection, or enrollment plan.